entertainment -WSS

entertainment

author：leisure time 2025-09-30 22:27:29 - browse：2842

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Key House panel plots a new health care package

WSS

Google and Epic fight stronger regulation of AI in health care

Why hospitals are withdrawing from US News rankings

Custom gene therapy hints at new path for rare disease treatments

An interview with Robert F. Kennedy Jr. on vaccines

Doctors find melanoma drugs effective against rare brain cancer

Hilary expected to bring catastrophic, life

focus

entertainment

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congress must give Medicare recipients genetic counseling access

Wildfire smoke exposes gaps in outdoor worker protections

Listen: Wegovy in the brain & pivotal Alzheimer's data

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Eye stem cell transplant could help restore vision in injured people

New air purifier tech could be key to improving indoor air quality

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Guidelines to prevent youth baseball injuries need more muscle

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

hotspot

Listen: Wegovy in the brain & pivotal Alzheimer's data

Patient advocates sound warning on FDA proposal on salt intake

Living with Hashimoto's and celiac disease, and med school, too

As digital health tech proliferates, a new institute aims to cut through hype

Doctors find melanoma drugs effective against rare brain cancer

Group opposing PBM reform sets lobbying record

focus

explore

hotspot

focus